Whitelogolarge.jpg
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. – MORF
19 juil. 2024 14h28 HE | Monteverde & Associates PC
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022...
johnson fistel.jpg
Morphic Under Investigation: Shareholders Are Encouraged to Contact Johnson Fistel for Their Options
02 nov. 2023 17h05 HE | Johnson Fistel, LLP
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its...
Capture_brand and logo.PNG
Morphic to Present at the Jefferies Global Healthcare Conference
06 juin 2023 16h05 HE | Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 mai 2023 10h30 HE | Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
Capture_brand and logo.PNG
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
25 avr. 2023 07h00 HE | Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
25 avr. 2023 06h59 HE | Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
MorphicLogo.jpg
Morphic Announces Participation in Upcoming Investor Conferences
03 sept. 2020 16h30 HE | Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
30 août 2019 13h00 HE | Morphic Therapeutic
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...